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Protamine reversal of heparin anticoagulation is as- 
sociated with adverse hemodynamic effects that may be 
attenuated with protamine pretreatment (PP). This 
study assesses the role of complement activation during 
these phenomena in adult cardiac surgery patients. 
Sixteen individuals undergoing cardiopulmonary by- 
pass were given intravenous normal saline or prota- 
mine (2 mg/kg) as a randomized pretreatment prior to 
undergoing heparin anticoagulation (400 IU/kg), coro- 
nary artery revascularization, and subsequent rever- 
sal of the anticoagulated state with protamine (4 mg/ 
kg). Blood pressure, pulmonary artery diastolic pres- 
sure (PAD), heart rate, and cardiac output (CO) were 
measured during and after pretreatment, prior to hepa- 
rin reversal by protamine, and for 10 min after rever- 
sal. Total hemolytic complement (CHSO), C3 conver- 
sion to C3b, CSa/CSa, platelet count, and white blood 
cell count (WBC) were also measured at the same time 
periods. No significant correlation existed between 
complement activation and hemodynamic events, as 
might have been evident by decreased CH50, increased 
C3 conversion to C3b, or elevations in C3a/CSa levels. 
PP significantly prevented the CO decrease occurring 
at 1 and 3 min following heparin reversal by protamine 
(-0.8 and -1.4 liters/min vs 0.1 and -0.2 liters/min, P 
< 0.05 and P c 0.01, respectively). Reversal hypoten- 
sion was less with PP, although PAD fell equally in 
both groups. WBC decreases after heparin reversal 
were less after PP (-26% vs -7%, P = 0.06). These 
data support the conclusion that, contrary to earlier re- 
ports, adverse hemodynamic and hematologic re- 
sponses accompanying protamine reversal of heparin 
anticoagulation do not appear to be correlated with ac- 
tivation of complement. In fact, those patients having 
the greatest C3a generation exhibited the least hemody- 
namic changes. 0 1991 Academic Press, Inc. 
1 To whom reprint requests should be addressed at University Hos- 
pital, 2210 THCC, 1500 East Medical Center Drive, Ann Arbor, MI 
48109-0329. 
INTRODUCTION 
Protamine sulfate, when used to reverse the anticoagu- 
lant effects of sodium heparin during cardiac and periph- 
eral vascular surgery, may result in undesirable hemody- 
namic and hematologic side effects including hypoten- 
sion, bradycardia, declines in cardiac output, pulmonary 
artery hypertension as well as hypotension, thrombocy- 
topenia and neutropenia [l-7]. In a prospective study of 
48 adults exposed to protamine sulfate during cardiopul- 
monary bypass, 4% exhibited sudden increases in airway 
pressure, acute pulmonary hypertension, and systemic 
hypotension [8]. Although catastrophic events are un- 
common, observable declines in blood pressure and car- 
diac output are common and form the basis for this 
study. Complement activation has been considered by 
other investigators to be a contributory cause to these 
responses [9-X]. In both dog and preliminary human 
studies from our center, we were not able to relate com- 
plement activation to adverse hemodynamic or hemato- 
logic events [ l-3,17]. The present investigation was de- 
signed to more precisely define the role of complement 
activation during protamine reversal of heparin antico- 
agulation in patients undergoing cardiopulmonary by- 
pass procedures with and without protamine pretreat- 
ment. 
METHODS 
Sixteen patients, 13 males and 3 females, ranging in 
age from 42 to 71 years (X 61) were studied. Patients 
received either pretreatment with normal saline (Group 
I) or protamine sulfate, 2 mg/kg (PP, Group II), as a 
4-min intravenous infusion. Assignment to one or the 
other of these groups was done in a random, blinded 
manner. Five minutes following the former pretreat- 
ment, patients were anticoagulated with intravenous so- 
dium heparin, 400 III/kg. An activated clotting time 
(ACT) was determined 3 min later, and once the ACT 
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TABLE 1 
Complement Activity in Group I Cardiopulmonary 
Bypass Patients: Saline Pretreatment prior to Hepa- 
rin- Anticoagulation 
C3 conversion? C3a** C5a$ 
CH50* (X0) (rg/mU (ndml) 
Prior to protamine 
administration 
3 min following 
54 21.2 4.1 14.8 
completion of 
protamine 
administration 63 21.6 4.6 15.9 
Note. Statistical analyses (paired t tests) comparing complement 
before and following protamine administration: *no activation, tP 
= 0.90, **p = 0.52, SP = 0.30. 
was documented to be ~400 set, patients were placed on 
cardiopulmonary bypass and underwent coronary revas- 
cularization. 
The cardiopulmonary bypass circuit oxygenator con- 
sisted of a Sci-Med (Sci-Med, Minneapolis, MN) or a 
Maxima (Medtronics, Minneapolis, MN) device. Oxy- 
genator priming solutions and cardioplegia solutions 
were the same in all patients. Mean cross-clamping time 
was 42 f 10 min with no differences between the groups 
(44 and 40 min in Groups I and II, respectively), while 
mean pump time was 81 + 28 min with again no differ- 
ences between groups (80 and 82 min in Groups I and II, 
respectively). At the conclusion of the arterial recon- 
struction, the anticoagulated state was reversed with in- 
travenous protamine, 4 mg/kg, infused over 8 min. All 
patients gave informed consent according to an ap- 
proved University of Michigan Human Use Committee 
protocol. 
Associated diseases in study patients, including 
chronic obstructive pulmonary disease, previous myo- 
cardial infarction, systemic arterial hypertension, and 
diabetes mellitus did not vary among the two pretreat- 
ment groups. The preoperative ejection fraction aver- 
aged greater than 50% in 12 patients, was unknown in 4 
patients, and was not significantly different between the 
two pretreatment groups. Coronary reconstruction in- 
volved at least two saphenous vein bypass grafts in all 
patients, and additional internal mammary artery by- 
passes were performed in 10 patients. 
Hemodynamic parameters measured during the study 
included mean systemic arterial blood pressure (BP) by 
way of an indwelling radial artery line; pulmonary artery 
diastolic pressure (PAD) by way of a Swan-Ganz cath- 
eter placed into the pulmonary artery; central venous 
pressure by way of a catheter placed into the internal 
jugular vein; heart rate from the arterial line tracing; and 
cardiac output (CO) measured by thermodilution tech- 
nique. Measurements were made during and after saline 
or protamine pretreatment, just prior to protamine re- 
versal of heparin anticoagulation at the conclusion of 
cardiopulmonary bypass, and for 10 min following pro- 
tamine reversal. Platelet counts and white blood cell 
counts were measured prior to pretreatment, after pre- 
treatment, after heparin administration, prior to prota- 
mine reversal, and at 1, 3, and 10 min following prota- 
mine reversal of heparin anticoagulation. 
Total hemolytic complement (CH50) and C3 conver- 
sion to C3b were measured prior to pretreatment, prior 
to protamine reversal, and 3 min after protamine rever- 
sal. CH50 was defined under rigidly standardized condi- 
tions as the quantity of complement necessary for 50% 
lysis of sheep red blood cells sensitized with rabbit anti- 
sheep red blood cell antibody. Conversion of C3 to C3b 
was assayed using crossed immunoelectrophoresis. The 
amount of C3 conversion was determined on the basis of 
the relative electrophoretic mobility of C3 and C3b. C3a 
and C5a plasma levels were measured prior to protamine 
reversal and 3 min after the conclusion of protamine 
administration using conventional radioimmunoassay 
techniques for C3a des Arg and C5a des Arg, respectively 
(Amersham, Arlington Heights, IL). Statistical evalua- 
tion of the data included use of paired and unpaired Stu- 
dent’s t tests and linear correlations where appropriate. 
Statistical significance was defined at P < 0.05. 
RESULTS 
Evidence of complement activation occurring as a 
consequence of protamine reversal of heparin anticoagu- 
lation was not forthcoming from data generated in this 
study (Tables 1 and 2). An increase in C3 conversion to 
C3b, from 13.4 t- 20.0 to 21.2 + 9.0% in Group I, and 
TABLE 2 
Complement Activity in Group II Cardiopulmonary 
Bypass Patients: Protamine Pretreatment prior to Hep- 
arin Anticoagulation 
C3 conversiont C3a** C5a$ 
CH50* (%o) k/ml) bdml) 
Prior to protamine 
administration 




43 20.5 3.2 10.3 
70 24.0 7.7 13.8 
Note. Statistical analyses (paired t tests) comparing complement 
before and following protamine administration: *no activation, tP 
= 0.23, **P = O.O2,$P = 0.20. 
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from 13.6 + 20.0 to 20.5 +_ 12.0% in Group II, occurred 
between baseline and just prior to protamine reversal. 
However, little activation was noted during actual pro- 
tamine exposure. In Group I, C3 conversion increased 
almost imperceptibly from 21.2 f 9.0 to 21.6 + 9.0% 
after reversal, and in Group II a similarly insignificant 
increase occurred from 20.5 +- 12.0 to 24.0 +- 18.5%. Di- 
minished total hemolytic complement, indicating com- 
plement activation, occurred between baseline and just 
prior to protamine reversal, with decreases of 135 f 64 to 
54 f 28 CH50 units noted in Group I, and decreases of 
112 2 17 to 43 & 26 CH50 units occurring in Group II. No 
complement activation occurred following protamine 
reversal in Group I patients, with an increase of CH50 
from 54 + 28 to 63 f 39 units being noted, or in Group II 
patients, with an increase in CH50 from 43 f 26 to 70 
* 39 CH50 units being evident. 
No correlations between obvious hemodynamic 
events and complement activity existed in this study. No 
significant correlation occurred between changes in 
CH50 and changes in BP in either treatment group after 
protamine reversal (P > 0.09). Similarly, no significant 
correlation existed between changes in CH50 and 
changes in CO in either treatment group at 1, 3, or 10 
min following protamine reversal (P 2 0.31). Finally, no 
significant correlation occurred between changes in 
CH50 and changes in PAD in either treatment group (P 
> 0.05). 
A lack of significant correlation was also observed 
when C3 conversion to C3b was compared to changes in 
CO in either treatment group (P 3 0.20). Isolated signifi- 
cant correlations were noted between declines in BP in 
Group II patients and elevations in C3 conversion to 
C3b 10 min after reversal (P = 0.02) and between de- 
clines in PAD in Group II patients and elevations in C3 
conversion to C3b 3 and 4 min after reversal (P < 0.05). 
C3a levels increased after protamine reversal from 4.1 
+ 2.2 to 4.6 + 1.8 @g/ml in Group I patients, and from 3.2 
f 1.2 to 7.7 f 5.0 pg/ml in Group II subjects. No signifi- 
cant correlations existed between C3a increases during 
protamine reversal and changes in BP (P > 0.06), CO (P 
2 0.05), or PAD (P 2 0.07). The highest generation of 
C3a was a 131% increase noted in Group II protamine 
pretreated patients (P < 0.05). A small increase in C5a 
levels occurred from 14.8 -t 3.4 to 15.9 f 2.2 rig/ml in 
Group I and 10.3 f 4.2 to 13.8 + 4.0 rig/ml in Group II. 
No significant correlations existed between C5a eleva- 
tions and changes in CO (P 2 0.20) or PAD (P 2 0.07). 
The only significant correlation between C5a elevations 
and BP changes occurred at 11 min after protamine re- 
versal in Group II where C5a elevation was related to BP 
decline (P < 0.05). 
Protamine pretreatment did prevent the fall in CO 
that occurred 1 and 3 min following heparin reversal by 
TABLE 3 
Cardiac Output Change in Cardiopulmonary Bypass 




Group I Group II 
(liters/min) (liters/min) 
1 min following 
completion of protamine 
administration -0.8 0.1 P < 0.05 
3 min following 
completion of protamine 
administration -1.4 -0.2 P < 0.01 
10 min following 
completion of protamine 
administration -1.4 -0.8 NS 
protamine (-0.8 and -1.4 liters/min vs 0.1 and -0.2 
liters/min P < 0.05, P < 0.01, respectively, Table 3). 
Protamine pretreatment diminished hypotension follow- 
ing protamine reversal, with the maximal mean drop in 
BP in Group I patients being -12 mm Hg vs -6 mm Hg 
in Group II patients, although these differences were not 
statistically different. There were no group differences 
in PAD changes. Similarly, no group differences oc- 
curred in the magnitude of thrombocytopenia, although 
there was a difference in the degree of leukopenia, with 
Group I and Group II changes being -25 +- 7 and -7 
f 22%, respectively (P = 0.06). The degree of thrombo- 
cytopenia occurring during pretreatment appeared re- 
lated to the drop in blood pressure observed at the con- 
clusion of protamine reversal (r2 = 0.55, P c 0.05), 5 min 
after the conclusion of reversal (r2 = 0.68, P c 0.05), as 
well as 7 min after the conclusion of reversal (r2 = 0.62, 
P < 0.05). 
Comparable numbers of Group I and II patients, (n 
= 6 and n = 7, respectively) required small amounts of 
additional heparin during cardiopulmonary bypass to 
maintain an activated clotting time of at least 400 sec. 
The total heparin dose per individual in Group I patients 
(35,000 + 8,000 IU) was less than the heparin dose in 
Group II patients (48,125 + 14,147 IU, P -c 0.05). At the 
conclusion of protamine reversal, similar numbers of 
Group I and II patients (n = 4 and n = 3, respectively) 
required additional protamine sulfate to reverse their 
heparin anticoagulation. 
DISCUSSION 
Complement activation has been purported to cause 
the adverse hemodynamic and hematologic side effects 
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accompanying protamine sulfate reversal of heparin an- 
ticoagulation. Early in vitro studies suggested that hepa- 
rin and protamine combinations, at levels below those 
causing complement activation by either substance 
alone, depleted total hemolytic complement in the fash- 
ion of an antibody-antigen complex through the classi- 
cal pathway of complement activation [lo, 111. These 
studies were followed by in vivo rabbit studies in which 
generation of C5a was implicated by the existence of a 
transient granulocytopenia produced by heparin-prota- 
mine interactions [ 121. Clinical investigations followed 
these former studies. 
In 100 cardiopulmonary bypass patients treated at the 
Mayo Clinic, C3a and C4a levels were measured at regu- 
lar intervals before and after administering protamine 
(1.3 mg/lOO IU heparin) over a 5- to lo-min interval 
[ 131. The protamine dosage in this Mayo Clinic study is 
approximately 10% greater than that in the present 
study. In this study, 90 patients received protamine 5 
min after the conclusion of the cardiopulmonary bypass, 
and 10 patients received protamine at the time of skin 
closure approximately 45 min after discontinuing the 
cardiopulmonary bypass. C4a was not activated during 
cardiopulmonary bypass in either group. However, C4a 
increased some twofold 10 min after protamine adminis- 
tration 5 min following bypass. C4a level did not in- 
crease with the delayed administration of protamine. 
Since C4a generation does not involve activation of 
complement by way of the alternate pathway, protamine 
most likely effected classical complement pathway acti- 
vation. C3a activation was also documented in this 
study. The authors concluded that complement activa- 
tion, pulmonary sequestration of leukocytes, lysosome 
enzyme release, superoxide generation, histamine re- 
lease from mast cells, and increased capillary perme- 
ability occurred in response to protamine reversal of hep- 
arin. Two facts about this study make it difficult to ex- 
trapolate its data to those of the present investigation. 
First, patients in the Mayo study did not exhibit reversal 
hypotension and thus correlations between hemody- 
namic changes and complement activation were not pos- 
sible. Second, the measurements in the Mayo study were 
obtained a full 10 min following protamine reversal, a 
time beyond that when adverse responses have been 
known to occur. 
A study similar to that from the Mayo Clinic was un- 
dertaken by Kirklin and his colleagues at the University 
of Alabama. In the latter investigation, 20 patients were 
given a mean protamine dose of 410 mg (approximately 
20% greater than the present study) over 5 min after 
cardiopulmonary bypass [14]. Peak levels of C3a and 
C4a occurred 10 min after the start of protamine admin- 
istration or 5 min after its completion. Thereafter, C3a 
levels fell steadily and were near normal at 24 hr. In the 
case of C4d, the peak C4d-C4 ratio occurred 5 min after 
protamine administration, and remained elevated for 48 
hr. No change in C5a was noted with protamine adminis- 
tration. A drop in white blood cell count from 9150 to 
6770 occurred in this study 1 min before to 5 min after 
protamine administration, and a fall in platelet count 
from 107,930 to 76,550 occurred during the same time 
interval. No patient in this study demonstrated an im- 
portant adverse hemodynamic reaction to protamine. 
In contrast to the two former clinical studies, a third 
report in humans undergoing cardiopulmonary bypass 
revealed no consumption of complement, particularly 
C3 and C4 [16]. However, in this latter study C3a and 
C4a levels were not quantitated, but instead total C3 and 
C4 was measured by radioimmunodiffusion. Such an as- 
say may not be sensitive enough to demonstrate comple- 
ment activation. 
We have assessed the relevance of complement acti- 
vation by protamine in three previous investigations, in- 
cluding two canine studies and one human study involv- 
ing patients undergoing abdominal aortic replacement 
[2, 3, 171. We were unable to demonstrate any correla- 
tion between hemodynamic changes and C3a generation 
or changes in total hemolytic complement. In one of the 
former canine studies, eight animals were depleted of 
complement by intraperitoneal administration of Baja 
n. nuja cobra venom factor, 20 units/kg, 48 and 24 hr (40 
units/kg total dose) prior to anticoagulation with hepa- 
rin and subsequent reversal with protamine [17]. De- 
spite confirmed decomplementation, the maximal hemo- 
dynamic changes in these animals were similar to those 
occurring in animals who were not complement de- 
pleted, including a BP decrease of -43 mm Hg, a heart 
rate decrease of -16, a PAD increase of +3 mm Hg, a CO 
decline of -27%, and platelet and white blood cell count 
declines of -49% and -48%, respectively. This study 
supports the conclusions that complement components 
C3 and C5 to C9 are not influential factors in causing 
protamine-heparin induced hemodynamic changes and 
that classical pathway activation is not a major factor 
contributing to these adverse responses. 
No relation was established in the present study be- 
tween total hemolytic complement, C3 conversion 
to C3b by crossed immunoelectrophoresis, or C3a/C5a 
anaphylatoxin levels and changes in BP, CO, or PAD. In 
fact, patients with the least fall in CO, those in Group II 
receiving protamine pretreatment, showed the highest 
plasma levels of C3a. Thus, complement activation in 
animals and humans following protamine administra- 
tion does not appear to be a primary cause of the hemody- 
namic and hematologic changes accompaning adminis- 
tration of this drug. 
C3 conversion (assessed by crossed immunoelectro- 
phoresis) during cardiopulmonary bypass is well known 
76 JOURNAL OF SURGICAL RESEARCH: VOL. 51, NO. 1, JULY 1991 
and has been reported to be 6.4% [ 181, a value similar to 
the 7.8% observed in the present study in Group I. Like- 
wise, complement activation during cardiopulmonary 
bypass, as measured by a fall in CH50, is well accepted 
and has been reported to be 25% [19], which is lower 
than the 60% encountered in our series in Group I. Re- 
garding C3a levels, we noted a little over a onefold in- 
crease in the Group I saline pretreatment group and an 
approximate twofold increase in the Group II protamine 
pretreated patients after reversal. In the Mayo Clinic 
study, there also was an approximate twofold increase in 
C3a levels measured prior to and after protamine rever- 
sal in the 90 patients who received protamine at the 
usual time after cardiopulmonary bypass, and in those 
receiving delayed administration of protamine, there 
was approximately a 50% increase [13]. The Alabama 
study documented a threefold increase in C3a after pro- 
tamine administration, but no significant generation of 
C5a. This was similar to our study where C5 activation 
was also much less than C3 activation with at most a 7% 
elevation of C5a noted in Group I and a 34% elevation of 
C5a noted in Group II patients. Thus, the magnitude of 
changes in all complement parameters measured in the 
present investigation were similar to those in previous 
reports. 
The principal difference between our study and earlier 
studies by others is the correlations drawn between com- 
plement activation and hemodynamic side effects. In 
fact, we found no significant correlations between com- 
plement activation and adverse hemodynamic side ef- 
fects. The present study strongly suggests that comple- 
ment activation from protamine-heparin interaction is 
not a primary factor in the production of adverse hemo- 
dynamic and hematologic changes associated with pro- 
tamine reversal of heparin anticoagulation. Although 
complement activation may occur in these patients, it 
does not appear to have a direct causal relation to the 
adverse reactions accompanying protamine administra- 
tion. 
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